Advance on the research and clinical treatment of gastrointestinal stromal tumors
- VernacularTitle:胃肠道间质瘤的研究和治疗进展
- Author:
Huajie ZHANG
;
Gang LI
- Publication Type:Journal Article
- Keywords:
gastrointestinal stromal tumors;
surgical treatment;
clinical pathology;
target therapeutic agents
- From:
China Oncology
2006;0(10):-
- CountryChina
- Language:Chinese
-
Abstract:
Gastrointestinal stromal tumors(GISTs) are rarely one of gastrointestinal carcinomas that originate from mesenchymal tissue.GISTs are characterized by expression of CD117 receptor in cells and have variable biological phenotypes ranging from benign to highly malignant.The most common complaints of patients with GISTs are abdominal pain,peptic ulcer,bleeding or/and obstruction in digestive tract.GISTs have an extraordinarily high rate of recurrence after surgical resection and are highly resistant to radiation and standard chemotherapy.The imatinib mesylate(Gleevec) is a selective inhibitor of the tyrosine kinase receptor.The outcome for the patients with GISTs treated by Gleevec was promising in terms of immediate response and survival fraction.Recent research shows that a new targeting therapeutic agent,SU11248,can prolong the survival time of the patients with GISTs who were resistant to Gleevec therapy.
